WealthPlan Investment Management LLC purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,009 shares of the medical research company’s stock, valued at approximately $598,000.
Several other institutional investors have also modified their holdings of the company. Level Four Advisory Services LLC grew its position in shares of Edwards Lifesciences by 3.7% during the third quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock worth $257,000 after acquiring an additional 119 shares during the last quarter. Colonial Trust Co SC grew its position in shares of Edwards Lifesciences by 0.4% during the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock worth $2,504,000 after acquiring an additional 120 shares during the last quarter. Evermay Wealth Management LLC lifted its holdings in Edwards Lifesciences by 4.0% in the fourth quarter. Evermay Wealth Management LLC now owns 3,304 shares of the medical research company’s stock worth $282,000 after purchasing an additional 128 shares during the period. Howard Capital Management Inc. lifted its holdings in Edwards Lifesciences by 3.3% in the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock worth $322,000 after purchasing an additional 132 shares during the period. Finally, Florida Trust Wealth Management Co lifted its holdings in Edwards Lifesciences by 1.5% in the fourth quarter. Florida Trust Wealth Management Co now owns 8,810 shares of the medical research company’s stock worth $751,000 after purchasing an additional 132 shares during the period. Institutional investors own 79.46% of the company’s stock.
Insider Buying and Selling at Edwards Lifesciences
In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $83.98, for a total value of $85,575.62. Following the completion of the sale, the vice president directly owned 33,682 shares of the company’s stock, valued at approximately $2,828,614.36. This represents a 2.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 88,096 shares of company stock valued at $7,288,799. 0.31% of the stock is owned by insiders.
Edwards Lifesciences Price Performance
Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the prior year, the company earned $0.64 EPS. Edwards Lifesciences’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several research firms recently weighed in on EW. Wells Fargo & Company upped their price objective on shares of Edwards Lifesciences from $96.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, February 11th. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Evercore reaffirmed an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a report on Friday, April 24th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $95.65.
View Our Latest Report on Edwards Lifesciences
About Edwards Lifesciences
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles
- Five stocks we like better than Edwards Lifesciences
- As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
